Dr Philip Gordts
Disclosure details
Dr Gordts is a Founder, Consultant and Board Member of Covicept TherapeuticsAssistant Professor in the Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, USA
Dr Philip Gordts is an Assistant Professor in the department of medicine, division of Endocrinology and Metabolism at the University of California, San Diego. He received a PhD in Biomedical Sciences from the Catholic University of Leuven in Belgium and completed postdoctoral training as a Marie Curie research fellow in glycobiology and metabolism at the University of California, San Diego with Prof. Jeffrey Esko in the US. For more than 20 years the work of Dr Gordts has focused on the role of hepatic lipoprotein receptors, their glycosylation and interaction with several apolipoproteins in regulating systemic lipid metabolism as well as inflammation and iron metabolism. Most recent research focusses on modulating the hepatic clearance of triglyceride protein remnants to attenuate progression and promote regression of atherosclerotic lesions.
Dr Gordts is a steering committee member of the Glycobiology Research and Training Center at the University of California, San Diego. Currently he serves as an associate editor for the journals Atherosclerosis, Glycobiology, Frontiers in Molecular Biosciences, and Frontiers in Cardiovascular Medicine. Dr. Gordts is the recipient of the 2020 National Center of Leadership in Academic Medicine Award, 2016 Journal of Lipid Research Junior Investigator Award, 2012 UCSD Chancellor’s Award for Outstanding Scholar, and a Marie Curie fellowship award.
